Eye­ing sec­ond Japan­ese ap­proval, Dai­ichi and Ex­elix­is an­nounce pos­i­tive piv­otal for kid­ney drug

Near­ly a year af­ter earn­ing reg­u­la­to­ry ap­proval against hy­per­ten­sion in Japan, Dai­ichi Sankyo an­nounced new pos­i­tive Phase III tri­al da­ta that could push them and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER